Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) EBITDA Margin (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed EBITDA Margin for 9 consecutive years, with 7057.38% as the latest value for Q1 2026.

  • For Q1 2026, EBITDA Margin fell 643261.0% year-over-year to 7057.38%; the TTM value through Mar 2026 reached 350.97%, up 44176.0%, while the annual FY2025 figure was 306.65%, 16850.0% up from the prior year.
  • EBITDA Margin hit 7057.38% in Q1 2026 for Bicycle Therapeutics, down from 42.1% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 42.1% in Q4 2025 and bottomed at 7057.38% in Q1 2026.
  • Average EBITDA Margin over 5 years is 1191.58%, with a median of 690.26% recorded in 2022.
  • Year-over-year, EBITDA Margin skyrocketed 147206bps in 2025 and then tumbled -643261bps in 2026.
  • Bicycle Therapeutics' EBITDA Margin stood at 358.56% in 2022, then crashed by -179bps to 999.59% in 2023, then crashed by -31bps to 1309.33% in 2024, then surged by 97bps to 42.1% in 2025, then plummeted by -16664bps to 7057.38% in 2026.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 7057.38%, 42.1%, and 504.58% for Q1 2026, Q4 2025, and Q3 2025 respectively.